Edition:
United States

Gilead Sciences Inc (GILD.OQ)

GILD.OQ on NASDAQ Stock Exchange Global Select Market

69.06USD
4:00pm EDT
Change (% chg)

$-1.17 (-1.67%)
Prev Close
$70.23
Open
$69.74
Day's High
$69.93
Day's Low
$68.92
Volume
2,152,525
Avg. Vol
2,529,609
52-wk High
$89.53
52-wk Low
$64.02

Chart for

About

Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company's portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS),... (more)

Overall

Beta: 1.15
Market Cap(Mil.): $91,317.32
Shares Outstanding(Mil.): 1,300.26
Dividend: 0.57
Yield (%): 3.25

Financials

  GILD.OQ Industry Sector
P/E (TTM): 10.32 240.92 34.18
EPS (TTM): 6.80 -- --
ROI: 17.33 -5.87 13.17
ROE: 43.65 -7.71 15.15

UPDATE 2-GSK's two-drug HIV treatment meets main goal in late stage studies

June 14 GlaxoSmithKline's two-drug treatment for HIV, the virus that causes AIDS, met its main goal in late stage studies, scoring key points in its rivalry with Gilead in the medical field.

Jun 14 2018

BRIEF-FDA Approves Expanded Indication For Truvada

* U.S. FOOD AND DRUG ADMINISTRATION APPROVES EXPANDED INDICATION FOR TRUVADA® (EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE) FOR REDUCING THE RISK OF ACQUIRING HIV-1 IN ADOLESCENTS

May 15 2018

BRIEF-Gilead's Kite Announces New Facilities, Expands Collaboration With National Cancer Institute

* KITE ANNOUNCES NEW WORLDWIDE FACILITIES AND EXPANDED COLLABORATION WITH NATIONAL CANCER INSTITUTE TO SUPPORT CELL THERAPY PIPELINE

May 15 2018

Gilead defeats nonprofit's challenge to AIDS treatment patents

A federal appeals court on Friday tossed a lawsuit brought by a nonprofit arguing Gilead Sciences Inc patents relating to several of its HIV/AIDS drugs are invalid.

May 11 2018

BRIEF-Gilead Sciences Board Has Declared A Cash Dividend Of $0.57 Per Share Of Common Stock For Q2 Of 2018

* GILEAD SCIENCES INC - BOARD OF DIRECTORS HAS DECLARED A CASH DIVIDEND OF $0.57 PER SHARE OF COMMON STOCK FOR Q2 OF 2018 Source text for Eikon: Further company coverage:

May 01 2018

BRIEF-Gilead Sciences Reports Q1 EPS $1.17

* GILEAD SCIENCES ANNOUNCES FIRST QUARTER 2018 FINANCIAL RESULTS

May 01 2018

Gilead hepatitis C drug sales slump, shares fall 5 percent

Gilead Sciences Inc reported a lower quarterly profit on Tuesday as sales of its flagship hepatitis C drugs fell by a greater-than-expected 59 percent, sending shares of the biotechnology company down 5 percent.

May 01 2018

UPDATE 1-Gilead hepatitis C drug sales slump, shares fall 5 pct

May 1 Gilead Sciences Inc reported a lower quarterly profit on Tuesday as sales of its flagship hepatitis C drugs fell by a greater-than-expected 59 percent, sending shares of the biotechnology company down 5 percent.

May 01 2018

Gilead hepatitis C drug sales slump, shares fall 6 percent

May 1 Gilead Sciences Inc reported a lower quarterly profit on Tuesday as sales of its flagship hepatitis C drugs fell by a greater-than-expected 59 percent, sending shares of the biotechnology company down nearly 6 percent.

May 01 2018

BRIEF-Gilead And Verily Announce Scientific Collaboration

* GILEAD AND VERILY ANNOUNCE SCIENTIFIC COLLABORATION TO IDENTIFY AND UNDERSTAND IMMUNOLOGICAL AND MOLECULAR DRIVERS OF INFLAMMATORY DISEASES

Apr 30 2018

Competitors

Earnings vs. Estimates